Designing better cancer immunotherapies using advanced computational methods
Official title: Structure-guided cancer immunotherapy design with HLA-Arena and CrossDome
Funded at University of Houston · NIH-10866859 · Data updated 2026-11-12
This study is looking for better ways to help your immune system fight Acute Myeloid Leukemia (AML) by finding safe and effective targets that can boost T-cells, using new technology to make the process easier and more effective.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $414,649 |
| NIH project number | 1R21CA289333-01 |
| Project ID | NIH-10866859 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Acute Myeloid Leukemia who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of cancer or those who do not have a diagnosis of Acute Myeloid Leukemia may not benefit from this research.
What this research studies
This research focuses on improving T-cell-based therapies for cancer, specifically targeting Acute Myeloid Leukemia (AML). It aims to identify safe and effective peptide targets that can activate T-cells without causing harmful side effects. By utilizing advanced structural modeling and machine learning techniques, the study will create a new computational environment called HLA-arena 2.0, which integrates various bioinformatics methods to enhance the discovery of tumor-associated antigens. This innovative approach seeks to overcome current limitations in identifying effective immunotherapy targets.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer and more effective immunotherapies for patients with Acute Myeloid Leukemia.
How similar studies have gone: Other research has shown promise in using structural modeling and machine learning for immunotherapy design, indicating that this approach could be a significant advancement in the field.
Where this research is happening
-
University of Houston
Houston, United States Active
Researchers
- Principal investigator: Antunes, Dinler — University of Houston
- Study coordinator: Antunes, Dinler
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.